Telstra’s vision for Anywhere Healthcare

Telstra's increasing range of eHealth solutions should be great for patients, but may disappoint any investors hoping it will turn the company into a growth stock.

In a country that made flying doctors famous, Telstra (ASX: TLS) is busy building the next phase of remote healthcare.

Telstra Health has already brought together a range of businesses offering:

On top of all this, Telstra’s ReadyCare service allows patients in remote areas, or that otherwise find it hard to attend personally (such as the elderly), to ‘talk directly with GPs over video or phone to receive advice, diagnosis, prescriptions and referrals’. The system also automatically shares treatment notes with a patient’s usual GP to allow continuity of care.

The purchase last week of Anywhere Healthcare from Medibank extends this service to specialist care via video link, although patients will have to get themselves along to one of 1,600 GPs and aged-care providers that currently offer the service. With help on the ground from the local GP or practice nurse, patients will have access to specialists in over 30 different practice areas.

Of course we’ve seen it all before, in a multitude of sci-fi films, and that makes it easy to scoff. But these innovations will make a huge difference to the quality and cost of healthcare provision, particularly for those in remote areas.

Fair enough, then, for Telstra to shout it all from the rooftops, to build acceptance and use of the various services – but it’s hard to see it moving the needle financially. Using the back of a hypothetical envelope, Australia has around 70,000 doctors, and if $10,000 a year was paid to Telstra in respect of every one of them, that would amount to revenues of $700m. Adding in the 257,000 nurses, also at $10,000 a year, would get you up to revenues of $3.3bn. Yet even this would amount to only 13% of Telstra’s 2014 revenue.

We wish Telstra the best of luck with its ‘eHealth’ ambitions for obvious reasons, but investors hoping it will turn it into a ‘growth stock’ are likely to be disappointed.

To get more insights, stock research and BUY recommendations, take a 15 day free trial of Intelligent Investor’s Share Advisor now.

Want access to our latest research and new buy ideas?

Start a free 15 day trial and gain access to our research, recommendations and market-beating model portfolios.

Sign up for free

Join the Conversation...

There are comments posted so far.

If you'd like to join this conversation, please login or sign up here

Related Articles